Dr. Erick Gamelin has served as Acrivon's Chief Development Officer since January 2024 and previously served as its Chief Medical Officer from March 2021. He was previously Chief Medical Officer at Step Pharma, Vice President, Oncology at Dynavax Technologies, Vice President at MacroGenics, and held leadership positions in oncology at Pfizer and Amgen. A medical oncologist and pharmacologist, he is a former professor of medical oncology and CEO of the French national university cancer center (ICO) and a Knight of the French National Order of Merit. He has led more than 100 Phase 1-3 oncology trials and co-authored over 135 peer-reviewed articles. Dr. Gamelin received his Ph.D. in molecular pharmacology from Bordeaux University and conducted post-doctoral studies at the NIH.